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Central nervous system involvement in Hodgkin lymphoma is extremely rare, especially
in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), which usually carries
a favorable prognosis. Here we report a case of a young patient with NLPHL, who
developed a progressive and fatal neurological deterioration requiring a very extensive
work-up including two biopsies to obtain the diagnosis of T-cell/histiocyte-rich large
B-cell lymphoma like transformation. This report, which includes post-mortem analysis,
highlights the correlations between clinical, radiological, and biological data but also the
difficulties encountered in reaching the correct diagnosis.
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INTRODUCTION
Central nervous system (CNS) lymphoma is very often a diagnostic challenge and has been
relatively frequently reported in systemic non-Hodgkin lymphoma (NHL) but very rarely in
Hodgkin lymphoma (HL) (1–3). The anatomical sites affected can be diverse, including isolated
leptomeningeal involvement (4). Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)
is a rare disease accounting for approximately 5–10% of HL (5) and affects predominantly males at
a median age of 30–35 years. It typically presents with stage I or II disease carrying a very favorable
prognosis with a 10-years overall survival of greater than 90%. However, approximately 20% of the
patients with advanced-stage NLPHL have an inferior survival, similar to classical HL (6), and tend
to relapse or transform to an aggressive B-cell lymphoma which may resemble T-cell/histiocyte-
rich large B-cell lymphoma (THRLBCL), or more usual diffuse large B-cell lymphoma (7). Here,
we report a case of a patient with NLPHL relapsing with meningeal involvement, manifested by
progressive and fatal neurological deterioration, and with THRLBCL-like transformation.
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CASE DESCRIPTION
A previously healthy 31-year-old man first presented in 2017 with
fever, asthenia, mild self-resolving headache, and pancytopenia.
PET-CT showed enlargement of multiple peripheral, thoracic,
and abdominal lymph nodes, several hypermetabolic foci in
the liver, splenomegaly and focal pancreatic uptake [maximal
standardized uptake value (SUV) 23.8, at hepatic hilum], and
an axillary lymph node biopsy (Figures 1A–D) showed NLPHL
comprising different immunoarchitectural patterns, mostly C
[nodular with many extranodular lymphocyte predominant (LP)
cells] and D (T-cell-rich nodular), with a minor component
of classical A pattern (B-cell rich nodular). The LP cells were
BCL2- CD10- lymphoid and the Epstein-Barr virus (EBV) was
negative by in situ hybridization. The bone marrow biopsy
was negative. The disease was therefore staged IV-B, with
an International Prognostic Score (IPS) score of 2/7. Six
cycles of R-CHOP (Rituximab-Cyclophosphamide Doxorubicin
Vincristine Prednisone) followed by two cycles of Rituximab
were administered between May and July 2017. An interim
PET-CT showed good partial response, while thoraco-abdominal
CT at the end of treatment showed a persisting right axillary
lymph node (1.8 cm) and slight splenomegaly, without focal
lesions. In the absence of an end-of-treatment PET-CT, the
patient was followed clinically. In February 2019 he reported
abdominal pain, vomiting, and weight loss. A bulging of the
gastric wall was observed through gastroscopy, and biopsies
(Figures 1E–G) revealed an atypical destructive lymphoid
infiltrate in the mucosa, containing a moderate number of
large CD79a+, BCL2+, CD10-lymphoid cells, surrounded by
abundant T cells, interpreted as relapse with THRLBCL-
like lymphoma. A PET-CT showed hypermetabolic abdominal
lymph nodes and several hypermetabolic foci with a maximum
SUV of approximatively 16, localizing to the stomach, small
bowel, pancreas, and spleen. Salvage chemotherapy [three cycles
of R-ICE (Ifosfamide Carboplatinum Etoposide)] induced a
complete metabolic response, followed by autologous stem cell
transplantation in May 2019 with no major complications.
Starting July 2019, he presented with a progressive headache,
neck stiffness, fever, and asthenia. The initial work-up showed
intracranial hypertension (up to 50 cm H2O), lymphocytic
meningitis (pleocytosis up to 220 cells/µl, between 80 and
95% lymphocytes), elevated cerebrospinal fluid (CSF) lactate
levels (up to 9 mmol/l), very low CSF-to-serum glucose levels
(ratio down to 0.12), increased CSF protein (up to 12 g/l), as
well as diffuse leptomeningeal and cranial nerve enhancement,
without any parenchymal lesion on magnetic resonance imaging
(Figure 2). Flow cytometry analyses on four consecutive
lumbar punctures found lymphocytic pleocytosis, with a
T-cell immunophenotype (both CD4+ and CD8+), and PCR
analyses showed polyclonal TRG gene rearrangements, while
cytopathological analyses concluded to small lymphocytes
without atypia and couldn’t disclose malignant cells. Despite
extensive search for infectious agents, no definitive diagnosis
could be established. Furthermore, no hypermetabolic foci were
found on PET-CT, nor abnormalities on slit lamp examination,
nor mass lesion on thoraco-abdominal CT. Empirical
administration of broad-spectrum antibiotics (including
antituberculotic agents), antifungals, IV immunoglobulins, and
IV steroids (up to 12 mg/d dexamethasone) were unsuccessful.
Clinical worsening was characterized by development of tetra-
appendicular ataxia and delirium, with persistent low-grade
fever. After a first inconclusive right frontal cerebro-meningeal
biopsy (showing only reactive gliosis), a second one, performed
1 month later in the same region (Figure 3), found on the
meningeal surface a tiny focus of large atypical lymphoid cells
with a CD20-/(+), CD79a+, CD10+, BCL2+, BCL6+, MYC+,
MUM1-, CD30- immunophenotype, admixed with fibrin and
a moderate amount of small CD3+ reactive T cells. The Ki67
proliferation fraction was >90%. It was concluded to a focus of
large B-cell lymphoma. Fluorescent in situ hybridization (FISH)
studies found no rearrangement of BCL2, BCL6, or MYC genes
while cytological examination of the CSF obtained at the same
time showed marked small-cell lymphocytosis with scattered
large atypical cells. B-cell clonality studies (IGH, IGK, and IGL
gene rearrangements) were non-contributive on the brain biopsy
but demonstrated monoclonal peaks in the CSF. The patient
received three injections of high-dose IV methylprednisolone
and high dose methotrexate (3 g/m2), but his clinical condition
did not improve and he finally died 3 months after the initial
neurological complaints. A brain autopsy was performed.
Histologically, the main finding was a diffuse cellular infiltrate
in the meningeal spaces, predominantly in the sulci, featuring
THRLBCL-like characteristics (Figure 4). The infiltrate consisted
of small CD3+ lymphocytes, histiocytes, and scattered large
hyperchromatic lymphoid cells that were positive for CD79a and
CD19. In situ hybridization for EBV was negative. No sheets of
large cells nor necrosis was observed.
DISCUSSION
The clinical course of this young patient, who presented with
advanced-stage NLPHL treated with R-CHOP frontline therapy,
was characterized by initial abdominal recurrence with visceral
involvement in the form of a THRLBCL-like transformation and
finally meningeal relapse. The incidence of transformation to
aggressive B-cell lymphoma in NLPHL is estimated in the range
of 7 to 10% at 10 years (8, 9), and the reported median time to
transformation is several years (8–10). Advanced stage disease
seems to be associated with a higher risk of transformation (8,
11), and there have been reports suggesting that most of the stage
III/IV patients harbor disease already transformed at the time
of presentation (12). This may have been the case also in our
patient where the maximum SUV observed on the first PET-CT
was above the usual values for NLPHL (13). Splenic involvement
may have been another risk factor of transformation (9). While
the variant histologic patterns of NLPHL have been found to
correlate with advanced disease at initial diagnosis, a higher risk
of recurrence and poor clinical outcomes after stage-adapted
first-line treatment (14), they have not been formally established
as risk for transformation.
The most unusual aspect of this case was the occurrence of a
second relapse with isolated CNS involvement. CNS involvement
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FIGURE 1 | Axillary lymph node biopsy (April 2017; A–D) and gastric biopsy (February 2019; E–G). (A) High power view of the lymph node shows a few large LP
cells scattered within a background of small lymphocytes and histiocytes. (B) CD20 immunostaining in a pattern A (classical) nodule highlighting many small B cells
and scattered large LP cells (red circles). (C) CD20 immunostaining in pattern C [nodular with many extranodular lymphocyte predominant (LP) cells] showing the
edge of a nodule (asterisk), and scattered large LP cells (red circles) outside of the nodule (D) CD20 immunostaining showing large CD20+ atypical cells (red circles)
arranged in large nodules with essentially no small B cells in the background (pattern D: T-cell-rich nodular). (E) Low-power view of the gastric biopsies showing a
dense and destructive cellular infiltrate. (F) The infiltrate comprises lymphoid cells including large atypical elements. (G) CD79a highlights the rather numerous large
atypical B cells.
FIGURE 2 | Selected axial T1 weighted images from brain MRI with contrast (A,B). (A) Diffuse gyriform leptomeningeal enhancement on both cerebral hemispheres.
(B) Enhancement of the cisternal portion of the right 6th cranial nerve (arrow).
in HL is extremely rare at diagnosis and in patients with relapsed
or refractory disease. In a recent study, Cheah et al. screened the
clinical data of more than 30,000 HL patients and identified only
21 cases with CNS involvement, corresponding to an incidence
<0.1% (3). Two retrospective series have reported a total of 37
HL patients with CNS involvement (2, 3). With the exception
of one case of NLPHL who had CNS involvement at the time
of the diagnosis, the other 36 cases were classical HL with
roughly half of them presenting CNS involvement at the time
of primary diagnosis, and the other half presenting CNS relapse.
Most cases were associated to parenchymal lesions identified by
brain imaging, and less than 25% of the cases had leptomeningeal
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FIGURE 3 | Brain biopsy (A–E) and CSF (F). (A) Low power view of the brain cortical biopsy showing cellular deposits on the meningeal surface. (B) The cellular foci
comprise many large atypical cells. (C) The latter are positive for CD79a. (D) CD3 stains many admixed small T cells. (E) Ki67 stains the nuclei of most large cells.
(F) CSF contains a few large atypical cells and many small lymphocytes.
FIGURE 4 | Brain autopsy. (A) Low power view of leptomeningeal spaces enlarged by a dense cellular infiltrate. (B) The infiltrate comprises scattered large lymphoid
cells (arrows), numerous small lymphocytes, and histiocytes. (C) CD79a highlights the large atypical B cells (arrows). (D) CD68 underscores the histiocyte-rich
background.
involvement only. A variety of unspecific neurological symptoms
have been described, including weakness, headache, pain and
sensory changes, altered mental status, seizures, or manifesting
with lymphocytic meningitis without visible lesions detectable
by imaging. Atypical cells were identified in the CSF in a
minority of cases, while increased protein levels in the CSF was
a common finding.
The patient reported here is the first well-documented case
of meningeal involvement in relapsed/transformed NLPHL.
This diagnosis has been excessively difficult requiring two
biopsies, and thus highlighting several key points that might
have delayed the diagnosis and subsequently treatment. In
addition to the very low likelihood of CNS involvement in
HL, the systemic disease was in remission. Metabolic and
imaging studies, which are usually sensitive in detecting relapsed
HL, failed to reveal any abnormal cerebral uptake. Therefore,
both the clinical picture and CSF characteristics suggested
an unknown infectious or reactive meningeal process. The
paucity of neoplastic cells and lack of parenchymal brain
involvement were further confounding factors. Post-mortem
analysis of the brain demonstrated widespread THRLBCL-like
histology involving solely the meninges, with no parenchymal
infiltrates, correlating very well with the clinical, biological,
and radiological findings. This case therefore illustrates that all
patients with NLPHL presenting with neurological symptoms
should undergo thorough neurologic investigation including
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detailed neuroimaging, CSF analysis with molecular testing for
clonality, and possibly brain biopsy. After exclusion of alternative
diagnoses, lymphoma should still be considered even if all the
aforementioned ancillary examinations come back negative.
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